Preprint Case Report Version 1 This version is not peer-reviewed

Molecular Characterization of a Long Term Survivor Double Metastatic Non Small Sell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy

Version 1 : Received: 12 May 2019 / Approved: 14 May 2019 / Online: 14 May 2019 (13:04:44 CEST)

How to cite: Brunetti, O.; Badalamenti, G.; De Summa, S.; Calabrese, A.; Argentiero, A.; Fucci, L.; Longo, V.; Perrotti, P.; Pinto, R.; Petriella, D.; Danza, K.; Tommasi, S.; Leonetti, F.; Silvestris, N. Molecular Characterization of a Long Term Survivor Double Metastatic Non Small Sell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. Preprints 2019, 2019050173 (doi: 10.20944/preprints201905.0173.v1). Brunetti, O.; Badalamenti, G.; De Summa, S.; Calabrese, A.; Argentiero, A.; Fucci, L.; Longo, V.; Perrotti, P.; Pinto, R.; Petriella, D.; Danza, K.; Tommasi, S.; Leonetti, F.; Silvestris, N. Molecular Characterization of a Long Term Survivor Double Metastatic Non Small Sell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. Preprints 2019, 2019050173 (doi: 10.20944/preprints201905.0173.v1).

Abstract

Management of multiple primary cancers, a not so infrequent event in oncology practice, is a critical issue due to the lack of literature . In this study, we reported the case of a patient with metachronous double metastatic non small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) who received gefitinib in combination with gemcitabine plus nab-paclitaxel and with mFOLFOX6 in first and second line, respectively. She achieved a progression free survival and an overall survival (OS) of 28 months for NSCLC and PFS-1 and OS of 20 and 13 months, respectively for PDAC. Moreover, the combination of gefitinib and chemotherapies treatments displayed a good safety profile. Given the insignificant frequency of this case, we performed a molecular characterization of both neoplasms with the aim to investigate the existence of particular activated pathways and/or similar immunological mutations. it is interesting to note that two neoplasms shared a commune mutation of B7-H3 gene, with the consecutive impairment of its expressed protein. In both PDAC and NSCLC, the expression of this protein was associated with a worse survival. Since B7-H3 is an anti-apoptotic protein, the reduction of its expression or function should justify a pro-apoptotic activity with a putative justification of the long survival of the patient considered in this report.

Subject Areas

Pancreatic ductal adenocarcinoma; non small cell lung cancer; double primary cancers; B7-H3; gefitinib; chemotherapy

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.